Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression

Authors: Nadarajah Vigneswaran, Darryl C Baucum, Jean Wu, Yahuan Lou, Jerry Bouquot, Susan Muller, Wolfgang Zacharias

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

TRAIL plays an important role in host immunosurveillance against tumor progression, as it induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and DcR2) receptors. Here, we compare the expression levels of TRAIL and its receptors in normal oral mucosa (NOM), oral premalignancies (OPM), and primary and metastatic oral squamous cell carcinomas (OSCC) in order to characterize the changes in their expression patterns during OSCC initiation and progression.

Methods

DNA microarray, immunoblotting and immunohistochemical analyses were used to examine the expression levels of TRAIL and its receptors in oral epithelial cell lines and in archival tissues of NOM, OPM, primary and metastatic OSCC. Apoptotic rates of tumor cells and tumor-infiltrating lymphocytes (TIL) in OSCC specimens were determined by cleaved caspase 3 immunohistochemistry.

Results

Normal oral epithelia constitutively expressed TRAIL, but expression was progressively lost in OPM and OSCC. Reduction in DcR2 expression levels was noted frequently in OPM and OSCC compared to respective patient-matched uninvolved oral mucosa. OSCC frequently expressed DR4, DR5 and DcR1 but less frequently DcR2. Expression levels of DR4, DR5 and DcR1 receptors were not significantly altered in OPM, primary OSCC and metastatic OSCC compared to patient-matched normal oral mucosa. Expression of proapoptotic TRAIL-receptors DR4 and DR5 in OSCC seemed to depend, at least in part, on whether or not these receptors were expressed in their parental oral epithelia. High DR5 expression in primary OSCC correlated significantly with larger tumor size. There was no significant association between TRAIL-R expression and OSSC histology grade, nodal status or apoptosis rates of tumor cells and TIL.

Conclusion

Loss of TRAIL expression is an early event during oral carcinogenesis and may be involved in dysregulation of apoptosis and contribute to the molecular carcinogenesis of OSCC. Differential expressions of TRAIL receptors in OSCC do not appear to play a crucial role in their apoptotic rate or metastatic progression.
Appendix
Available only for authorised users
Literature
1.
Kemp TJ, Kim JS, Crist SA, Griffith TS: Induction of necrotic tumor cell death by TRAIL/Apo-2L. Apoptosis. 2003, 8 (6): 587-599. 10.1023/A:1026286108366.CrossRefPubMed
2.
Wajant H, Pfizenmaier K, Scheurich P: TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002, 7 (5): 449-459. 10.1023/A:1020039225764.CrossRefPubMed
3.
Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002, 2 (6): 420-430. 10.1038/nrc821.CrossRefPubMed
4.
Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004, 95 (10): 777-783. 10.1111/j.1349-7006.2004.tb02181.x.CrossRefPubMed
5.
Griffith TS, Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998, 10 (5): 559-563. 10.1016/S0952-7915(98)80224-0.CrossRefPubMed
6.
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997, 277 (5327): 818-821. 10.1126/science.277.5327.818.CrossRefPubMed
7.
Vigneswaran N, Wu J, Nagaraj N, Adler-Storthz K, Zacharias W: Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis. Int J Oncol. 2005, 26 (1): 103-112.PubMed
8.
Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12 (3): 228-237. 10.1038/sj.cgt.7700792.CrossRefPubMed
9.
Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA: The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis. Immunol Invest. 2006, 35 (3-4): 279-296. 10.1080/08820130600745463.CrossRefPubMed
10.
Nagaraj NS, Vigneswaran N, Zacharias W: Hypoxia inhibits TRAIL-induced tumor cell apoptosis: Involvement of lysosomal cathepsins. Apoptosis. 2007, 12 (1): 125-139. 10.1007/s10495-006-0490-1.CrossRefPubMed
11.
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999, 104 (2): 155-162.CrossRefPubMedPubMedCentral
12.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999, 5 (2): 157-163. 10.1038/5517.CrossRefPubMed
13.
Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A: Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000, 97 (4): 1754-1759. 10.1073/pnas.030545097.CrossRefPubMedPubMedCentral
14.
Gliniak B, Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 1999, 59 (24): 6153-6158.PubMed
15.
Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, Belka C: Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer. 2005, 5: 5-10.1186/1471-2407-5-5.CrossRefPubMedPubMedCentral
16.
Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C: Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene. 2006, 25 (37): 5145-5154.PubMed
17.
Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 2005, 92 (8): 1430-1441. 10.1038/sj.bjc.6602487.CrossRefPubMedPubMedCentral
18.
Shankar S, Srivastava RK: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat. 2004, 7 (2): 139-156. 10.1016/j.drup.2004.03.002.CrossRefPubMed
19.
Finnberg N, El-Deiry WS: Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. Clin Cancer Res. 2006, 12 (14 Pt 1): 4132-4136. 10.1158/1078-0432.CCR-06-0567.CrossRefPubMed
20.
21.
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001, 7 (1): 94-100. 10.1038/83416.CrossRefPubMed
22.
Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ: Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003, 63 (1): 207-213.PubMed
23.
Rowinsky EK: Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 2005, 23 (36): 9394-9407. 10.1200/JCO.2005.02.2889.CrossRefPubMed
24.
Fukuda M, Hamao A, Tanaka A, Kitada M, Suzuki S, Kusama K, Sakashita H: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity. Oncol Rep. 2003, 10 (5): 1113-1119.PubMed
25.
Teng MS, Brandwein-Gensler MS, Teixeira MS, Martignetti JA, Duffey DC: A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2005, 131 (5): 407-412. 10.1001/archotol.131.5.407.CrossRefPubMed
26.
Sacks PG: Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev. 1996, 15 (1): 27-51. 10.1007/BF00049486.CrossRefPubMed
27.
Vigneswaran N, Beckers S, Waigel S, Mensah J, Wu J, Mo J, Fleisher KE, Bouquot J, Sacks PG, Zacharias W: Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol. 2006, 80 (2): 147-159. 10.1016/j.yexmp.2005.09.011.CrossRefPubMed
28.
Vigneswaran N, Wu J, Sacks P, Gilcrease M, Zacharias W: Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. J Oral Pathol Med. 2005, 34 (2): 77-86. 10.1111/j.1600-0714.2004.00258.x.CrossRefPubMed
29.
Park NH, Gujuluva CN, Baek JH, Cherrick HM, Shin KH, Min BM: Combined oral carcinogenicity of HPV-16 and benzo(a)pyrene: an in vitro multistep carcinogenesis model. Oncogene. 1995, 10 (11): 2145-2153.PubMed
30.
Pindborg JJ, Reichart PA, Smith CJ, der. WJ: Histological Typing of Cancer and Precancer of the Oral Mucosa WHO. 1997, New York , Springer, 2ndCrossRef
31.
Gown AM, Willingham MC: Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem. 2002, 50 (4): 449-454.CrossRefPubMed
32.
Vigneswaran N, Zhao W, Dassanayake A, Muller S, Miller DM, Zacharias W: Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Hum Pathol. 2000, 31 (8): 931-937. 10.1053/hupa.2000.9035.CrossRefPubMed
33.
Nagaraj NS, Vigneswaran N, Zacharias W: Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells. J Cancer Res Clin Oncol. 2006, 132 (3): 171-183. 10.1007/s00432-005-0053-9.CrossRefPubMed
34.
Jalving M, de Jong S, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J, de Vries EG, Kleibeuker JH: TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res. 2006, 12 (14 Pt 1): 4350-4356. 10.1158/1078-0432.CCR-05-2487.CrossRefPubMed
35.
Lu X, Arbiser JL, West J, Hoedt-Miller M, Sheridan A, Govindarajan B, Harral JW, Rodman DM, Fouty B: Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells. Am J Pathol. 2004, 165 (5): 1613-1620.CrossRefPubMedPubMedCentral
36.
Popnikolov NK, Gatalica Z, Adegboyega PA, Norris BA, Pasricha PJ: Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma. Appl Immunohistochem Mol Morphol. 2006, 14 (2): 161-165. 10.1097/01.pai.0000157905.30872.9f.CrossRefPubMed
37.
Stander S, Schwarz T: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer. Am J Dermatopathol. 2005, 27 (2): 116-121. 10.1097/01.dad.0000154401.45465.ee.CrossRefPubMed
38.
Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Moller P, Lehnert T: Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res. 2002, 8 (12): 3734-3740.PubMed
39.
Xu J, Zhou JY, Wu GS: Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 2006, 66 (20): 10092-10099. 10.1158/0008-5472.CAN-06-1633.CrossRefPubMed
40.
Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H: Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. Embo J. 2004, 23 (15): 3051-3060. 10.1038/sj.emboj.7600302.CrossRefPubMedPubMedCentral
41.
Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM: Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem. 2002, 277 (39): 36602-36610. 10.1074/jbc.M206306200.CrossRefPubMed
42.
Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006, 24 (17): 2666-2672. 10.1200/JCO.2005.04.8306.CrossRefPubMed
43.
Lazarus P, Sheikh SN, Ren Q, Schantz SP, Stern JC, Richie JP, Park JY: p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis. 1998, 19 (3): 509-514. 10.1093/carcin/19.3.509.CrossRefPubMed
44.
El-Deiry WS: Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001, 8 (11): 1066-1075. 10.1038/sj.cdd.4400943.CrossRefPubMed
45.
Winn DM: Epidemiology of cancer and other systemic effects associated with the use of smokeless tobacco. Adv Dent Res. 1997, 11 (3): 313-321.CrossRefPubMed
46.
Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de Jong S: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol. 2003, 200 (3): 327-335. 10.1002/path.1364.CrossRefPubMed
47.
McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM: Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res. 2006, 12 (12): 3856-3863. 10.1158/1078-0432.CCR-06-0190.CrossRefPubMedPubMedCentral
48.
McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM: Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005, 11 (14): 5188-5194. 10.1158/1078-0432.CCR-05-0158.CrossRefPubMed
49.
Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF: Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004, 109 (5): 786-792. 10.1002/ijc.20041.CrossRefPubMed
50.
Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res. 2003, 9 (9): 3397-3405.PubMed
51.
Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ, el-Deiry WS: p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998, 58 (8): 1593-1598.PubMed
52.
Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A: Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol. 2001, 3 (4): 409-416. 10.1038/35070096.CrossRefPubMed
53.
Frey AB, Monu N: Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol. 2006, 79 (4): 652-662. 10.1189/jlb.1105628.CrossRefPubMed
54.
Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL: Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002, 8 (10): 3137-3145.PubMed
55.
Koyama S: Differential expression of intracellular apoptotic signaling molecules in tumor and tumor-infiltrating lymphocytes during development of invasion and/or metastasis of gastric carcinoma. Dig Dis Sci. 2003, 48 (12): 2290-2300. 10.1023/B:DDAS.0000007865.96569.9a.CrossRefPubMed
56.
Barnes L, Ferlito A, Altavilla G, MacMillan C, Rinaldo A, Doglioni C: Basaloid squamous cell carcinoma of the head and neck: clinicopathological features and differential diagnosis. Ann Otol Rhinol Laryngol. 1996, 105 (1): 75-82.CrossRefPubMed
57.
Altavilla G, Mannara GM, Rinaldo A, Ferlito A: Basaloid squamous cell carcinoma of oral cavity and oropharynx. ORL J Otorhinolaryngol Relat Spec. 1999, 61 (3): 169-173.CrossRefPubMed
58.
O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996, 184 (3): 1075-1082. 10.1084/jem.184.3.1075.CrossRefPubMed
59.
Koyama S, Koike N, Adachi S: Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol. 2002, 128 (2): 73-79. 10.1007/s004320100292.CrossRefPubMed
Metadata
Title
Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression
Authors
Nadarajah Vigneswaran
Darryl C Baucum
Jean Wu
Yahuan Lou
Jerry Bouquot
Susan Muller
Wolfgang Zacharias
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-108

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Satisfaction with care among patients with non-metastatic breast cancer: development and first steps of validation of the REPERES-60 questionnaire

Research article

Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study

Research article

Aberrant over-expression of a forkhead family member, FOXO1A, in a brain tumor cell line

Research article

Leucine-rich diet alters the eukaryotic translation initiation factors expression in skeletal muscle of tumour-bearing rats

Research article

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines

Research article

The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits